Xilio Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis
Xilio Therapeutics, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Innovative masked immuno-oncology platform with promising clinical data and adequate runway, but execution-dependent with meaningful binary development risk ahead. Phase 2 vilastobart data showed a 40% ORR in heavily pretreated MSS mCRC patients without liver metastases with promising response correlation to plasma TMB. However, as a clinical-stage biotech with.
What is Xilio Therapeutics, Inc.'s industry? Xilio Therapeutics, Inc. (xiliotx.com) operates in Biotechnology / Immuno-Oncology. AskCyborg classifies Xilio Therapeutics, Inc. under Biotechnology / Immuno-Oncology in its company registry.
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies with the goal of significantly improving outcomes for people living with cancer without...
Cyborg Score thesis
Innovative masked immuno-oncology platform with promising clinical data and adequate runway, but execution-dependent with...
Read the full analyst-debate transcript →Get the Latest Xilio Therapeutics, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeXilio Therapeutics, Inc. Overview
Pro stress-test →Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company leverages its proprietary masking technology to advance a pipeline of novel, masked I-O molecules designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment.
Strategic Profile
Pro stress-test →Key programs include vilastobart, an investigational tumor-activated, Fc-enhanced anti-CTLA-4 antibody being studied in combination with atezolizumab, and efarindodekin alfa (XTX301), a tumor-activated IL-12 in Phase 1/2 trials. The company has approximately $137.5 million in cash as of December 31, 2025, with funding extending its anticipated cash runway into Q2 2027.
Competitive Landscape
Pro stress-test →Xilio competes in the immuno-oncology space against established checkpoint inhibitor providers (Bristol Myers Squibb, Merck, Roche) and emerging cytokine/bispecific platforms. The masking technology represents a differentiation strategy to reduce systemic toxicity. Key competitive advantage lies in potentially achieving better therapeutic index through tumor-localized activation.
Industry Context
Xilio Therapeutics, Inc. operates in Biotechnology / Immuno-Oncology.
Key facts
Founded: 2016 · Headquarters: Waltham, Massachusetts